MarketWatch News on ALPMF
Japan stocks drop, as China shares extend gains 2:30 a.m. April 6, 2012 - V. Phani Kumar
Japan shares edge lower as yen strengthens 7:36 p.m. Oct. 25, 2010 - Myra P. Saefong
Japan shares range-bound in early trade, pre-data 7:38 p.m. June 27, 2010 - Myra P. Saefong
Japanese shares end the morning session higher 10:04 p.m. June 23, 2010 - Myra P. Saefong
Japan shares fall; pharmaceuticals among decliners 7:36 p.m. May 16, 2010 - Myra P. Saefong
Japan shares climb as chip maker shares advance 7:35 p.m. May 12, 2010 - Myra P. Saefong
Japan budget highlights fiscal quandary 12:01 a.m. March 3, 2010 - Lisa Twaronite
Japanese drug makers put up a fight 10:29 p.m. March 2, 2010 - Myra P. Saefong
Japan shares near flat as drug makers weaken 7:35 p.m. March 2, 2010 - Myra P. Saefong
Japan shares up; chip makers gain amid Nasdaq rise 7:28 p.m. March 1, 2010 - Myra P. Saefong
Updates, advisories and surprises 7:31 p.m. Aug. 3, 2009 - MarketWatch
Astellas Pharma profit, sales slip on stronger yen 1:38 a.m. Aug. 3, 2009 - Lisa Twaronite
Astellas Pharma April-June net profit 44.0 bln yen 1:17 a.m. Aug. 3, 2009 - Lisa Twaronite
FDA panel urges clearance for Cardiome-Astellas heart drug 3:55 a.m. Dec. 12, 2007 - Robert Daniel
Stocks in focus for Thursday 6:00 p.m. May 30, 2007 - MarketWatch
Theravance: EMEA validates telavancin application 4:01 p.m. May 30, 2007 - Gabriel Madway
Stocks in focus for Tuesday 6:08 p.m. May 14, 2007 - MarketWatch
CV Therapeutics submits regadenoson application to FDA 3:38 p.m. May 14, 2007 - Gabriel Madway
Stocks in focus for Wednesday 7:41 p.m. Feb. 20, 2007 - MarketWatch
Theravance: FDA accepts NDA for telavancin 5:56 p.m. Feb. 20, 2007 - Gabriel Madway
Loading more headlines...
Advertisement
Other News on ALPMF
FibroGen on deck for IPO 1:46 p.m. Nov. 10, 2014 - Seeking Alpha
10-Q: MEDIVATION, INC. 4:54 p.m. Nov. 6, 2014 - Edgar Online - (EDG = 10Q, 10K)
Astellas antifungal tagged an Orphan Drug 12:44 p.m. Nov. 3, 2014 - Seeking Alpha
Astellas Pharma's (ALPMF) CEO Yoshihiko Hatanaka on Q2 2014 Results - Earnings Call Transcript 1:33 p.m. Oct. 31, 2014 - Seeking Alpha
CHMP supports Xtandi label expansion 9:14 a.m. Oct. 24, 2014 - Seeking Alpha
10-Q: MEDIVATION, INC. 3:34 p.m. Aug. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Astellas Pharma's (ALPMF) Q2 2014 Results - Earnings Call Transcript 12:07 p.m. Aug. 1, 2014 - Seeking Alpha
Medivation, Astellas look to widen use of Xtandi cancer drug 8:12 a.m. March 18, 2014 - Seeking Alpha
Aveo, Astellas ending Tivozanib deal, colon-cancer work halted 7:29 a.m. Feb. 14, 2014 - Seeking Alpha
Ram Selvaraju: A Pair Of Companies Ride The Sea Change In Cancer Therapeutics 2:22 p.m. Feb. 7, 2014 - Seeking Alpha
Aveo ends trial of cancer drug due to low enrollment 7:46 a.m. Jan. 30, 2014 - Seeking Alpha
Seattle Genetics Will Exceed And Immunogen Will Meet Market Expectations 11:09 a.m. Jan. 25, 2014 - Seeking Alpha
Aveo says lead drug unlikely to succeed in colon cancer study, -15% 11:06 a.m. Dec. 13, 2013 - Seeking Alpha
10-Q: MEDIVATION, INC. 4:33 p.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
The New Doctor in the House: Consolidation 5:01 a.m. Feb. 3, 2011 - SmartMoney
Astellas's Strong Treatment For OSI 3:49 p.m. March 1, 2010 - The Wall Street Journal Interactive Edition
Press Releases on ALPMF
Changing Tomorrow Day 2014 Marks Astellas' Fifth Annual Global Service Initiative 1:22 a.m. Nov. 4, 2014 - PR Newswire - PRF
In 2023, Medivation/Astellas Pharma's Xtandi Will Be the Top-Selling Agent in the Prostate Cancer Market Across the United States, Europe, and Japan 12:00 p.m. Oct. 30, 2014 - PR Newswire - PRF
Vical Reports Third Quarter 2014 Financial Results and Progress in Key Development Programs 5:31 a.m. Oct. 30, 2014 - GlobeNewswire
QIAGEN Announces Broad Agreement With Astellas Pharma to Develop Companion Diagnostics 3:00 p.m. Oct. 28, 2014 - PR Newswire - PRF
Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study 12:20 a.m. Oct. 16, 2014 - GlobeNewswire
Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study 12:16 a.m. Oct. 16, 2014 - Thomson Reuters ONE
Astellas Teams Up with USA Rugby and Men's Health Network to Encourage Chicagoans to Answer the Challenge for Better Health 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
Astellas Announces Research Collaboration With Harvard Medical School Investigator For Treatment Of Retinal Degeneration 7:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
Cytokinetics Announces Development Program Update for CK-2127107 6:31 a.m. Oct. 13, 2014 - Thomson Reuters ONE
Brian McLellan Promoted to President of Astellas Pharma Technologies 4:31 p.m. Oct. 1, 2014 - PR Newswire - PRF
U.S. FDA Approves New Indication for the Use of XTANDI® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer 3:39 p.m. Sept. 10, 2014 - PR Newswire - PRF
Cancer Research UK and Cancer Research Technology Join Forces with Astellas on Autophagy to Find New Cancer Treatments 8:00 a.m. Aug. 8, 2014 - PR Newswire - PRF
Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs 5:02 a.m. July 31, 2014 - GlobeNewswire
Global Parkinson%s Disease Market 2014-2018 5:42 p.m. July 28, 2014 - PR Newswire - PRF
Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 3:27 p.m. July 15, 2014 - PR Newswire - PRF
Donna Ambrosino Joins ClearPath Vaccines Company as Chief Medical Officer 8:00 a.m. July 15, 2014 - PR Newswire - PRF
Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients 10:50 a.m. June 23, 2014 - PR Newswire - PRF
Astellas Pharma Returns to 'Give Kids The World' and Expands Partnership with Starlight Children's Foundation to Brighten the Lives of Young Patients & Their Families 8:00 a.m. June 11, 2014 - PR Newswire - PRF
Nidec Corp. Retains Top Spot on Institutional Investor's All-Japan Executive Team 1:45 a.m. June 5, 2014 - Marketwire
New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial of Enzalutamide in Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy 8:02 a.m. June 1, 2014 - Marketwire
Loading more headlines...